Accordingly, instead of circulating levels of BDNF in the first days after stroke, the sustaining reduction of peripheral BDNF expression at the acute stage is likely to correlate with poor clinical outcomes in patients with AIS. The gene discussed is BDNF; the disease is stroke disorder.